Parcourir par auteur "Fernandez-Nebro, A."
Voici les éléments 1-4 de 4
-
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Montes, A.; Perez-Pampin, E.; Joven, B.; Carreira, P.; Fernandez-Nebro, A.; Ordonez, M. D.; Navarro-Sarabia, F.; Moreira, V.; Vasilopoulos, Y.; Sarafidou, T.; Caliz, R.; Ferrer, M. A.; Canete, J. D.; de la Serna, A. R.; Magallares, B.; Narvaez, J.; Gomez-Reino, J. J.; Gonzalez, A. (2015)Objectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other Fc gamma R functional polymorphisms. ... -
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis
Marquez, A.; Ferreiro-Iglesias, A.; Davila-Fajardo, C. L.; Montes, A.; Pascual-Salcedo, D.; Perez-Pampin, E.; Moreno-Ramos, M. J.; Garcia-Portales, R.; Navarro, F.; Moreira, V.; Magro, C.; Caliz, R.; Ferrer, M. A.; Alegre-Sancho, J. J.; Joven, B.; Carreira, P.; Balsa, A.; Vasilopoulos, Y.; Sarafidou, T.; Cabeza-Barrera, J.; Narvaez, J.; Raya, E.; Canete, J. D.; Fernandez-Nebro, A.; Ordonez, M. D.; de la Serna, A. R.; Magallares, B.; Gomez-Reino, J. J.; Gonzalez, A.; Martin, J. (2014)Introduction: In this study, our aim was to elucidate the role of four polymorphisms identified in a prior large genome-wide association study (GWAS) in which the investigators analyzed the responses of patients with ... -
REDUCED CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS SHOWING IGG1 ALLOTYPE -INFLIXIMAB INCOMPATIBILITY
Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Serna, A. R.; Magallanes, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D. C.; Narvaez, J.; Canete, J. D.; Isaacs, J.; Morgan, A.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Bragggss (2013) -
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study
Montes, A.; Perez-Pampin, E.; Navarro-Sarabia, F.; Moreira, V.; de la Sema, A. R.; Magallares, B.; Vasilopoulos, Y.; Sarafidou, T.; Fernandez-Nebro, A.; Ordonez, M. D.; Narvaez, J.; Canete, J. D.; Marquez, A.; Pascual-Salcedo, D.; Joven, B.; Carreira, P.; Moreno-Ramos, M. J.; Caliz, R.; Ferrer, M. A.; Garcia-Portales, R.; Blanco, F. J.; Magro, C.; Raya, E.; Valor, L.; Alegre-Sancho, J. J.; Balsa, A.; Martin, J.; Plant, D.; Isaacs, J.; Morgan, A. W.; Barton, A.; Wilson, A. G.; Gomez-Reino, J. J.; Gonzalez, A.; Braggss (2015)Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor ...